Erratum: ‘Corrigendum to “2017 Taiwan lipid guidelines for high risk patients” [Journal of the Formosan Medical Association (2017) [217–248]’(S0929664616304302)(10.1016/j.jfma.2016.11.013);2017 Taiwan lipid guidelines for high risk patients

Journal of the Formosan Medical Association

Volumn 116, Issue 4, 2017, Pages 217-248

  Li, Yi Heng ^a   Ueng, Kwo Chang ^b,c   Jeng, Jiann Shing ^d   Charng, Min Ji ^e,f   Lin, Tsung Hsien ^g,h   Chien, Kuo Liong ^d,i   Wang, Chih Yuan ^d   Chao, Ting Hsing ^a   Liu, Ping Yen ^a   Su, Cheng Huang ^j,k   Chien, Shih Chieh ^j   Liou, Chia Wei ^l   Tang, Sung Chun ^d   Lee, Chun Chuan ^j   Yu, Tse Ya ^m   Chen, Jaw Wen ^e,f   Wu, Chau Chung ^d   Yeh, Hung I ^j,k  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

^g KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

ⁱ NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^j MACKAY MEMORIAL HOSPITAL   (Taiwan)

^k MACKAY MEDICAL COLLEGE   (Taiwan)

^l CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^m FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

more..

Author keywords

guidelines; high risk; hyperlipidemia; statin; Taiwan

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MIPOMERSEN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PROPROTEIN CONVERTASE 9; TRIACYLGLYCEROL; HYPOCHOLESTEROLEMIC AGENT;

ACUTE CORONARY SYNDROME; ALCOHOL CONSUMPTION; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; COMBINATION DRUG THERAPY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DIETARY SUPPLEMENT; DYSLIPIDEMIA; EXERCISE; FOLLOW UP; GENETICS; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; LIFESTYLE MODIFICATION; MEDICAL LITERATURE; OCCLUSIVE CEREBROVASCULAR DISEASE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PREGNANCY; REVIEW; RISK FACTOR; TAIWAN; TRANSIENT ISCHEMIC ATTACK; WEIGHT REDUCTION; ATHEROSCLEROSIS; BLOOD; COMPLICATION; HEALTHY DIET; HYPERLIPIDEMIAS; LIFESTYLE;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CHOLESTEROL, LDL; HEALTHY DIET; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIFE STYLE; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; TAIWAN;

EID: 85013797430     PISSN: 09296646     EISSN: 18760821     Source Type: Journal    
DOI: 10.1016/j.jfma.2018.07.007     Document Type: Erratum

References (220)

1. 1 Lee, C.H., Cheng, C.L., Yang, Y.H., Chao, T.H., Chen, J.Y., Liu, P.Y., et al. Trends in the incidence and management of acute myocardial infarction from 1999 to 2008: get with the guidelines performance measures in Taiwan. J Am Heart Assoc, 3, 2014, e001066.
2. 2 Yin, W.H., Lu, T.H., Chen, K.C., Cheng, C.F., Lee, J.C., Liang, F.W., et al. The temporal trends of incidence, treatment, and in-hospital mortality of acute myocardial infarction over 15 years in a Taiwanese population. Int J Cardiol 209 (2016), 103–113.
3. 3 Pan, W.H., Wu, H.J., Yeh, C.J., Chuang, S.Y., Chang, H.Y., Yeh, N.H., et al. Diet and health trends in Taiwan: comparison of two nutrition and health surveys from 1993–1996 and 2005–2008. Asia Pac J Clin Nutr 20 (2011), 238–250.
4. 4 Ho, L.T., Yin, W.H., Chuang, S.Y., Tseng, W.K., Wu, Y.W., Hsieh, I.C., et al., Taiwanese Secondary Prevention for patients with AtheRosCLErotic disease (T-SPARCLE) Registry Investigators. Determinants for achieving the LDL-C target of lipid control for secondary prevention of cardiovascular events in Taiwan. PLoS One, 10, 2015, e0116513.
5. 5 Shyu, K.G., Wu, C.J., Mar, G.Y., Hou, C.G.Y., Li, A.H., Wen, M.S., et al. Clinical characteristics, management and in-hospital outcomes of patients with acute coronary syndrome — observations from the Taiwan ACS Full Spectrum Registry. Acta Cardiol Sin 27 (2011), 135–144.
6. 6 Hsieh, F.I., Lien, L.M., Chen, S.T., Bai, C.H., Sun, M.C., Tseng, H.P., et al., Taiwan Stroke Registry Investigators. Get with the guidelines-stroke performance indicators: surveillance of stroke care in the Taiwan Stroke Registry: get with the guidelines-stroke in Taiwan. Circulation 122 (2010), 1116–1123.
7. 7 Danaei, G., Singh, G.M., Paciorek, C.J., Lin, J.K., Cowan, M.J., Finucane, M.M., et al., Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group. The global cardiovascular risk transition: associations of four metabolic risk factors with national income, urbanization, and Western diet in 1980 and 2008. Circulation 127 (2013), 1493–1502 1502e1–8.
8. 8 Farzadfar, F., Finucane, M.M., Danaei, G., Pelizzari, P.M., Cowan, M.J., Paciorek, C.J., et al., Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Cholesterol). National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet 377 (2011), 578–586.
9. 9 Pan, W.H., Chiang, B.N., Plasma lipid profiles and epidemiology of atherosclerotic diseases in Taiwan—a unique experience. Atherosclerosis 118 (1995), 285–295.
10. 10 Chang, H.Y., Yeh, W.T., Chang, Y.H., Tsai, K.S., Pan, W.H., Prevalence of dyslipidemia and mean blood lipid values in Taiwan: results from the Nutrition and Health Survey in Taiwan (NAHSIT, 1993–1996). Chin J Physiol 45 (2002), 187–197.
11. 11 Chien, K.L., Sung, F.C., Hsu, H.C., Su, T.C., Chang, W.D., Lee, Y.T., Relative importance of atherosclerotic risk factors for coronary heart disease in Taiwan. Eur J Cardiovasc Prev Rehabil 12 (2005), 95–101.
12. 12 Chien, K.L., Hsu, H.C., Su, T.C., Chen, M.F., Lee, Y.T., Hu, F.B., Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese. J Lipid Res 48 (2007), 2499–2505.
13. 13 Dattilo, A.M., Kris-Etherton, P.M., Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 56 (1992), 320–328.
14. 14 Shaw, K., Gennat, H., O'Rourke, P., Del Mar, C., Exercise for overweight or obesity. Cochrane Database Syst Rev, 4, 2006, CD003817.
15. 15 Seron, P., Lanas, F., Pardo Hernandez, H., Bonfill Cosp, X., Exercise for people with high cardiovascular risk. Cochrane Database Syst Rev, 8, 2014, CD009387.
16. 16 Fernandez, M.L., Dietary cholesterol provided by eggs and plasma lipoproteins in healthy populations. Curr Opin Clin Nutr Metab Care 9 (2006), 8–12.
17. 17 Shin, J.Y., Xun, P., Nakamura, Y., He, K., Egg consumption in relation to risk of cardiovascular disease and diabetes: a systematic review and meta-analysis. Am J Clin Nutr 98 (2013), 146–159.
18. 18 Mensink, R.P., Zock, P.L., Kester, A.D., Katan, M.B., Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 77 (2003), 1146–1155.
19. 19 Mozaffarian, D., Aro, A., Willett, W.C., Health effects of trans-fatty acids: experimental and observational evidence. Eur J Clin Nutr 63 (2009), S5–S21.
20. 20 Brown, L., Rosner, B., Willett, W.W., Sacks, F.M., Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 69 (1999), 30–42.
21. 21 U.S. Department of Health and Human Services, U.S. Department of Agriculture, 2015–2020 dietary guidelines for Americans. 8th ed., December 2015 Available at: http://health.gov/dietaryguidelines/2015/guidelines/.
22. 22 Wood, P.D., Stefanick, M.L., Dreon, D.M., Frey-Hewitt, B., Garay, S.C., Williams, P.T., et al. Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. N Engl J Med 319 (1988), 1173–1179.
23. 23 Kraus, W.E., Houmard, J.A., Duscha, B.D., Knetzger, K.J., Wharton, M.B., McCartney, J.S., et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 347 (2002), 1483–1492.
24. 24 Chiang, C.E., Wang, T.D., Ueng, K.C., Lin, T.H., Yeh, H.I., Chen, C.Y., et al. 2015 guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension. J Chin Med Assoc 78 (2015), 1–47.
25. 25 Rimm, E.B., Williams, P., Fosher, K., Criqui, M., Stampfer, M.J., Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ 319 (1999), 1523–1528.
26. 26 Rabkin, S.W., Effect of cigarette smoking cessation on risk factors for coronary atherosclerosis. A control clinical trial. Atherosclerosis 53 (1984), 173–184.
27. 27 Yoon, C., Goh, E., Park, S.M., Cho, B., Effects of smoking cessation and weight gain on cardiovascular disease risk factors in Asian male population. Atherosclerosis 208 (2010), 275–279.
28. 28 Nordmann, A.J., Nordmann, A., Briel, M., Keller, U., Yancy, W.S. Jr., Brehm, B.J., et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med 166 (2006), 285–293.
29. 29 Stanhope, K.L., Schwarz, J.M., Keim, N.L., Griffen, S.C., Bremer, A.A., Graham, J.L., et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 119 (2009), 1322–1334.
30. 30 Bantle, J.P., Raatz, S.K., Thomas, W., Georgopoulos, A., Effects of dietary fructose on plasma lipids in healthy subjects. Am J Clin Nutr 72 (2000), 1128–1134.
31. 31 Eslick, G.D., Howe, P.R., Smith, C., Priest, R., Bensoussan, A., Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol 136 (2009), 4–16.
32. 32 Tokede, O.A., Gaziano, J.M., Djoussé, L., Effects of cocoa products/dark chocolate on serum lipids: a meta-analysis. Eur J Clin Nutr 65 (2011), 879–886.
33. 33 Gerards, M.C., Terlou, R.J., Yu, H., Koks, C.H., Gerdes, V.E., Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain — a systematic review and meta-analysis. Atherosclerosis 240 (2015), 415–423.
34. 34 Sacks, F.M., Lichtenstein, A., Van Horn, L., Harris, W., Kris-Etherton, P., Winston, M., American Heart Association Nutrition Committee. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 113 (2006), 1034–1044.
35. 35 Nissen, S.E., Tuzcu, E.M., Schoenhagen, P., Brown, B.G., Ganz, P., Vogel, R.A., et al., REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004), 1071–1080.
36. 36 Nissen, S.E., Nicholls, S.J., Sipahi, I., Libby, P., Raichlen, J.S., Ballantyne, C.M., et al., ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 (2006), 1556–1565.
37. 37 Cannon, C.P., Steinberg, B.A., Murphy, S.A., Mega, J.L., Braunwald, E., Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 48 (2006), 438–445.
38. 38 Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher, J., O'Connell, R., Voysey, M., Emberson, J., Blackwell, L., Mihaylova, B., et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385 (2015), 1397–1405.
39. 39 Baigent, C., Landray, M.J., Reith, C., Emberson, J., Wheeler, D.C., Tomson, C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377 (2011), 2181–2192.
40. 40 Cannon, C.P., Blazing, M.A., Giugliano, R.P., McCagg, A., White, J.A., Theroux, P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
41. 41 Sabatine, M.S., Giugliano, R.P., Wiviott, S.D., Raal, F.J., Blom, D.J., Robinson, J., et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372 (2015), 1500–1509.
42. 42 Robinson, J.G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372 (2015), 1489–1499.
43. 43 Navarese, E.P., Kolodziejczak, M., Schulze, V., Gurbel, P.A., Tantry, U., Lin, Y., et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med 163 (2015), 40–51.
44. 44 Cashin-Hemphill, L., Mack, W.J., Pogoda, J.M., Sanmarco, M.E., Azen, S.P., Blankenhorn, D.H., Beneficial effects of colestipol–niacin on coronary atherosclerosis: a 4-year follow-up. JAMA 264 (1990), 3013–3017.
45. 45 Brown, B.G., Zhao, X.-Q., Chait, A., Fisher, L.D., Cheung, M.C., Morse, J.S., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001), 1583–1592.
46. 46 The AIM-HIGH Investigators, Boden, W.E., Probstfield, J.L., Anderson, T., Chaitman, B.R., Desvignes-Nickens, P., Koprowicz, K., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365 (2011), 2255–2267.
47. 47 The HPS2-THRIVE Collaborative Group, Landray, M.J., Haynes, R., Hopewell, J.C., Parish, S., Aung, T., Tomson, J., et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371 (2014), 203–212.
48. 48 Lavigne, P.M., Karas, R.H., The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol 61 (2013), 440–446.
49. 49 Frick, M.H., Elo, O., Haapa, K., Heinonen, O.P., Heinsalmi, P., Helo, P., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 (1987), 1237–1245.
50. 50 Rubins, H.B., Robins, S.J., Collins, D., Fye, C.L., Anderson, J.W., Elam, M.B., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999), 410–418.
51. 51 Bezafibrate Infarction Prevention (BIP) Study, Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 102 (2000), 21–27.
52. 52 Keech, A., Simes, R.J., Barter, P., Best, J., Scott, R., Taskinen, M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005), 1849–1861.
53. 53 ACCORD Study Group, Ginsberg, H.N., Elam, M.B., Lovato, L.C., Crouse, J.R. 3rd, Leiter, L.A., Linz, P., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1563–1574.
54. 54 Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open label, blinded endpoint analysis. Lancet 369 (2007), 1090–1098.
55. 55 Kastelein, J.J., Maki, K.C., Susekov, A., Ezhov, M., Nordestgaard, B.G., Machielse, B.N., et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J Clin Lipidol 8 (2014), 94–106.
56. 56 Su, T.C., Hwang, J.J., Huang, K.C., Chiang, F.T., Chien, K.L., Wang, K.Y., et al. A randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ethyl-ester omega-3 fatty acid in Taiwanese hypertriglyceridemic patients. J Atheroscler Thromb, 2016 Sep 6 [Epub ahead of print].
57. 57 Nissen, S.E., Tardif, J.C., Nicholls, S.J., Revkin, J.H., Shear, C.L., Duggan, W.T., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 (2007), 1304–1316.
58. 58 Schwartz, G.G., Olsson, A.G., Abt, M., Ballantyne, C.M., Barter, P.J., Brumm, J., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367 (2012), 2089–2099.
59. 59 Schwartz, G.G., Olsson, A.G., Ezekowitz, M.D., Ganz, P., Oliver, M.F., Waters, D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001), 1711–1718.
60. 60 Cannon, C.P., Braunwald, E., McCabe, C.H., Rader, D.J., Rouleau, J.L., Belder, R., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004), 1495–1504.
61. 61 de Lemos, J.A., Blazing, M.A., Wiviott, S.D., Lewis, E.F., Fox, K.A., White, H.D., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292 (2004), 1307–1316.
62. 62 Okazaki, S., Yokoyama, T., Miyauchi, K., Shimada, K., Kurata, T., Sato, H., et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study. Circulation 110 (2004), 1061–1068.
63. 63 Dohi, T., Miyauchi, K., Okazaki, S., Yokoyama, T., Yanagisawa, N., Tamura, H., et al. Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a follow-up study. Atherosclerosis 210 (2010), 497–502.
64. 64 Spencer, F.A., Goldberg, R.J., Gore, J.M., Fox, K.A., Avezum, A., Agnelli, G., et al. Comparison of utilization of statin therapy at hospital discharge and six-month outcomes in patients with an acute coronary syndrome and serum low-density lipoprotein > or =100 mg/dl versus <100 mg/dl. Am J Cardiol 100 (2007), 913–918.
65. 65 Lee, K.H., Jeong, M.H., Kim, H.M., Ahn, Y., Kim, J.H., Chae, S.C., et al. Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol. J Am Coll Cardiol 58 (2011), 1664–1671.
66. 66 Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., Bhala, N., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
67. 67 Zhao, S.P., Yu, B.L., Peng, D.Q., Huo, Y., The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: results of the CHILLAS trial. Atherosclerosis 233 (2014), 707–712.
68. 68 Tsujita, K., Sugiyama, S., Sumida, H., Shimomura, H., Yamashita, T., Yamanaga, K., et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol 66 (2015), 495–507.
69. 69 Tsujita, K., Yamanaga, K., Komura, N., Sakamoto, K., Sugiyama, S., Sumida, H., et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE-IVUS trial. Atherosclerosis 251 (2016), 367–372.
70. 70 Nicholls, S.J., Hsu, A., Wolski, K., Hu, B., Bayturan, O., Lavoie, A., et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol 55 (2010), 2399–2407.
71. 71 Li, Y.H., Wu, H.L., Yang, Y.H., Tsai, H.S., Chao, T.H., Effect of early versus late in-hospital initiation of statin therapy on the clinical outcomes of patients with acute coronary syndrome. Int Heart J 48 (2007), 677–688.
72. 72 Saab, F.A., Eagle, K.A., Kline-Rogers, E., Fang, J., Otten, R., Mukherjee, D., Michigan Cardiovascular Outcomes Research and Reporting Program of the University of Michigan Cardiovascular Center. Comparison of outcomes in acute coronary syndrome in patients receiving statins within 24 hours of onset versus at later times. Am J Cardiol 94 (2004), 1166–1168.
73. 73 Navarese, E.P., Kowalewski, M., Andreotti, F., van Wely, M., Camaro, C., Kolodziejczak, M., et al. Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 113 (2014), 1753–1764.
74. 74 Miller, M., Cannon, C.P., Murphy, S.A., Qin, J., Ray, K.K., Braunwald, E., PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 51 (2008), 724–730.
75. 75 Schwartz, G.G., Abt, M., Bao, W., DeMicco, D., Kallend, D., Miller, M., et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol 65 (2015), 2267–2275.
76. 76 Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A.B., Frikke-Schmidt, R., Nordestgaard, B.G., Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 61 (2013), 427–436.
77. 77 Boekholdt, S.M., Arsenault, B.J., Mora, S., Pedersen, T.R., LaRosa, J.C., Nestel, P.J., et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 307 (2012), 1302–1309.
78. 78 The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998), 1349–1357.
79. 79 Sacks, F.M., Pfeffer, M.A., Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G., et al., Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996), 1001–1009.
80. 80 The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994), 1383–1389.
81. 81 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002), 7–22.
82. 82 LaRosa, J.C., Grundy, S.M., Waters, D.D., Shear, C., Barter, P., Fruchart, J.C., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005), 1425–1435.
83. 83 Puri, R., Nicholls, S.J., Shao, M., Kataoka, Y., Uno, K., Kapadia, S.R., et al. Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol 65 (2015), 1273–1282.
84. 84 Takayama, T., Hiro, T., Yamagishi, M., Daida, H., Hirayama, A., Saito, S., et al. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J 73 (2009), 2110–2117.
85. 85 Lee, C.W., Kang, S.J., Ahn, J.M., Song, H.G., Lee, J.Y., Kim, W.J., et al. Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial). Am J Cardiol 109 (2012), 1700–1704.
86. 86 Gao, W.Q., Feng, Q.Z., Li, Y.F., Li, Y.X., Huang, Y., Chen, Y.M., et al. Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound. BMC Cardiovasc Disord, 14, 2014, 60.
87. 87 LaRosa, J.C., Grundy, S.M., Kastelein, J.J., Kostis, J.B., Greten, H., Treating to New Targets (TNT) Steering Committee and Investigators. Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol 100 (2007), 747–752.
88. 88 Pedersen, T.R., Olsson, A.G., Faergeman, O., Kjekshus, J., Wedel, H., Berg, K., et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97 (1998), 1453–1460.
89. 89 Barter, P., Gotto, A.M., LaRosa, J.C., Maroni, J., Szarek, M., Grundy, S.M., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357 (2007), 1301–1310.
90. 90 Duran, N.E., Duran, I., Gürel, E., Gündüz, S., Göl, G., Biteker, M., et al. Coronary artery disease in patients with peripheral artery disease. Heart Lung 39 (2010), 116–120.
91. 91 Chen, I.C., Lee, C.H., Chao, T.H., Tseng, W.K., Lin, T.H., Chung, W.J., et al. Impact of routine coronary catheterization in low extremity artery disease undergoing percutaneous transluminal angioplasty: study protocol for a multi-center randomized controlled trial. Trials, 17, 2016, 112.
92. 92 Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 45 (2007), 645–654.
93. 93 Pedersen, T.R., Kjekshus, J., Pyörälä, K., Olsson, A.G., Cook, T.J., Musliner, T.A., et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 81 (1998), 333–335.
94. 94 Mondillo, S., Ballo, P., Barbati, R., Guerrini, F., Ammaturo, T., Agricola, E., et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 114 (2003), 359–364.
95. 95 Aronow, W.S., Nayak, D., Woodworth, S., Ahn, C., Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at 6 months and one year after treatment. Am J Cardiol 92 (2003), 711–712.
96. 96 Mohler, E.R. 3rd, Hiatt, W.R., Creager, M.A., Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108 (2003), 1481–1486.
97. 97 Aung, P.P., Maxwell, H., Jepson, R.G., Price, J., Leng, G.C., Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev, 4, 2007, CD000123.
98. 98 Meade, T., Zuhrie, R., Cook, C., Cooper, J., Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ, 325, 2002, 1139.
99. 99 West, A.M., Anderson, J.D., Meyer, C.H., Epstein, F.H., Wang, H., Hagspiel, K.D., et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis 218 (2011), 156–162.
100. 100 Zhang, X., Patel, A., Horibe, H., Wu, Z., Barzi, F., Rodgers, A., et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 32 (2003), 563–572.
101. 101 Yaghi, S., Elkind, M.S., Lipids and cerebrovascular disease: research and practice. Stroke 46 (2015), 3322–3328.
102. 102 Prospective Studies Collaboration, Lewington, S., Whitlock, G., Clarke, R., Sherliker, P., Emberson, J., Halsey, J., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370 (2007), 1829–1839.
103. 103 Tirschwell, D.L., Smith, N.L., Heckbert, S.R., Lemaitre, R.N., Longstreth, W.T. Jr., Psaty, B.M., et al. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 63 (2004), 1868–1875.
104. 104 Imamura, T., Doi, Y., Arima, H., Yonemoto, K., Hata, J., Kubo, M., et al. LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study. Stroke 40 (2009), 382–388.
105. 105 Cui, R., Iso, H., Yamagishi, K., Saito, I., Kokubo, Y., Inoue, M., et al. High serum total cholesterol levels is a risk factor of ischemic stroke for general Japanese population: the JPHC study. Atherosclerosis 221 (2012), 565–569.
106. 106 Iso, H., Jacobs, D.R. Jr., Wentworth, D., Neaton, J.D., Cohen, J.D., Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med 320 (1989), 904–910.
107. 107 Nagasawa, S.Y., Okamura, T., Iso, H., Tamakoshi, A., Yamada, M., Watanabe, M., et al. Relation between serum total cholesterol level and cardiovascular disease stratified by sex and age group: a pooled analysis of 65,594 individuals from 10 cohort studies in Japan. J Am Heart Assoc, 1, 2012, e001974.
108. 108 Wang, X., Dong, Y., Qi, X., Huang, C., Hou, L., Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis. Stroke 44 (2013), 1833–1839.
109. 109 Amarenco, P., Labreuche, J., Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 8 (2009), 453–463.
110. 110 Liu, C.H., Chen, T.H., Lin, M.S., Hung, M.J., Chung, C.M., Cherng, W.J., et al. Ezetimibe–simvastatin therapy reduce recurrent ischemic stroke risks in type 2 diabetic patients. J Clin Endocrinol Metab 101 (2016), 2994–3001.
111. 111 Amarenco, P., Bogousslavsky, J., Callahan, A. 3rd, Goldstein, L.B., Hennerici, M., Rudolph, A.E., et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006), 549–559.
112. 112 Amarenco, P., Benavente, O., Goldstein, L.B., Callahan, A. 3rd, Sillesen, H., Hennerici, M.G., et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke 40 (2009), 1405–1409.
113. 113 Goldstein, L.B., Amarenco, P., Szarek, M., Callahan, A. 3rd, Hennerici, M., Sillesen, H., et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 70 (2008), 2364–2370.
114. 114 McKinney, J.S., Kostis, W.J., Statin therapy and the risk of intracerebral hemorrhage — a meta-analysis of 31 randomized controlled trials. Stroke 43 (2012), 2149–2156.
115. 115 Chang, C.H., Lin, C.H., Caffrey, J.L., Lee, Y.C., Liu, Y.C., Lin, J.W., et al. Risk of intracranial hemorrhage from statin use in Asians: a nationwide cohort study. Circulation 131 (2015), 2070–2078.
116. 116 Antonopoulos, A.S., Margaritis, M., Lee, R., Channon, K., Antoniades, C., Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 18 (2012), 1519–1530.
117. 117 Ní Chróinín, D., Asplund, K., Åsberg, S., Callaly, E., Cuadrado-Godia, E., Díez-Tejedor, E., et al. Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials. Stroke 44 (2013), 448–456.
118. 118 Hong, K.S., Lee, J.S., Statins in acute ischemic stroke: a systematic review. J Stroke 17 (2015), 282–301.
119. 119 Meseguer, E., Mazighi, M., Lapergue, B., Labreuche, J., Sirimarco, G., Gonzalez-Valcarcel, J., et al. Outcomes after thrombolysis in AIS according to prior statin use: a registry and review. Neurology 79 (2012), 1817–1823.
120. 120 O'Brien, E.C., Greiner, M.A., Xian, Y., Fonarow, G.C., Olson, D.M., Schwamm, L.H., et al. Clinical effectiveness of statin therapy after ischemic stroke: primary results from the statin therapeutic area of the patient-centered research into outcomes stroke patients prefer and effectiveness research (PROSPER) study. Circulation 132 (2015), 1404–1413.
121. 121 Yeh, P.S., Lin, H.J., Bai, C.H., Hsieh, F.I., Ke, D.S., Li, Y.H., Effect of in-hospital initiation of lipid-lowering therapy on six-month outcomes in patients with acute ischemic stroke or transient ischemic attack. Am J Cardiol 105 (2010), 1490–1494.
122. 122 Jeng, J.S., Chuang, C.C., Chuang, S.Y., Chuang, S.Y., Yeh, H.I., Fang, C.C., et al. Guideline-adherent therapy in patients with cardiovascular diseases in Taiwan. J Formos Med Assoc 114 (2015), 1000–1007.
123. 123 Jung, J.M., Choi, J.Y., Kim, H.J., Seo, W.K., Statin use in spontaneous intracerebral hemorrhage: a systematic review and meta-analysis. Int J Stroke 10 (2015), 10–17.
124. 124 Chen, P.S., Cheng, C.L., Chang, Y.C., Kao Yang, Y.H., Yeh, P.S., Li, Y.H., Early statin therapy in patients with acute intracerebral hemorrhage without prior statin use. Eur J Neurol 22 (2015), 773–780.
125. 125 Labreuche, J., Deplanque, D., Touboul, P.J., Bruckert, E., Amarenco, P., Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis: systematic review and meta-regression analysis. Atherosclerosis 212 (2010), 9–15.
126. 126 Wang, D., Liu, B., Tao, W., Hao, Z., Liu, M., Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev, 10, 2015, CD009580.
127. 127 Keene, D., Price, C., Shun-Shin, M.J., Francis, D.P., Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ, 349, 2014, g4379.
128. 128 Constantinou, J., Jayia, P., Hamilton, G., Best evidence for medical therapy for carotid artery stenosis. J Vasc Surg 58 (2013), 1129–1139.
129. 129 Huang, Y., Li, W., Dong, L., Li, R., Wu, Y., Effect of statin therapy on the progression of common carotid artery intima-media thickness: an updated systematic review and meta-analysis of randomized controlled trials. J Atheroscler Thromb 20 (2013), 108–121.
130. 130 Giannopoulos, A., Kakkos, S., Abbott, A., Naylor, A.R., Richards, T., Mikhailidis, D.P., et al. Long-term mortality in patients with asymptomatic carotid stenosis: implications for statin therapy. Eur J Vasc Endovasc Surg 50 (2015), 573–582.
131. 131 Wörlund, S.M., Kurz, M.W., Hegland, O., Brønnick, K., Munk, P.S., Larsen, J.P., Treatment with statins improves long-term survival in individuals with carotid artery stenosis. Int J Cardiol 168 (2013), 624–626.
132. 132 Sillesen, H., Amarenco, P., Hennerici, M.G., Callahan, A., Goldstein, L.B., Zivin, J., et al. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Stroke 39 (2008), 3297–3302.
133. 133 Jeng, J.S., Tang, S.C., Liu, H.M., Epidemiology, diagnosis and management of intracranial atherosclerotic disease. Expert Rev Cardiovasc Ther 8 (2010), 1423–1432.
134. 134 Qureshi, A.I., Caplan, L.R., Intracranial atherosclerosis. Lancet 383 (2014), 984–998.
135. 135 Chimowitz, M.I., Lynn, M.J., Howlett-Smith, H., Stern, B.J., Hertzberg, V.S., Frankel, M.R., et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 352 (2005), 1305–1316.
136. 136 Chaturvedi, S., Turan, T.N., Lynn, M.J., Kasner, S.E., Romano, J., Cotsonis, G., et al. Risk factor status and vascular events in patients with symptomatic intracranial stenosis. Neurology 69 (2007), 2063–2068.
137. 137 Mok, V.C., Lam, W.W., Chen, X.Y., Wong, A., Ng, P.W., Tsoi, T.H., et al. Statins for asymptomatic middle cerebral artery stenosis: the regression of cerebral artery stenosis study. Cerebrovasc Dis 28 (2009), 18–25.
138. 138 Tan, T.Y., Kuo, Y.L., Lin, W.C., Chen, T.Y., Effect of lipid-lowering therapy on the progression of intracranial arterial stenosis. J Neurol 256 (2009), 187–193.
139. 139 Kim, B.J., Hong, K.S., Cho, Y.J., Lee, J.H., Koo, J.S., Park, J.M., et al. Predictors of symptomatic and symptomatic intracranial atherosclerosis: what is different and why?. J Atheroscler Thromb 21 (2014), 605–617.
140. 140 Chimowitz, M.I., Lynn, M.J., Derdeyn, C.P., Turan, T.N., Fiorella, D., Lane, B.F., et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 365 (2011), 993–1003.
141. 141 Derdeyn, C.P., Chimowitz, M.I., Lynn, M.J., Fiorella, D., Turan, T.N., Janis, L.S., et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet 383 (2014), 333–341.
142. 142 Waters, M.F., Hoh, B.L., Lynn, M.J., Kwon, H.M., Turan, T.N., Derdeyn, C.P., et al. Factors associated with recurrent ischemic stroke in the medical group of the SAMMPRIS trial. JAMA Neurol 73 (2016), 308–315.
143. 143 American Diabetes Association, Standards of medical care in diabetes—2016. Diabetes Care 39 (2016), S1–S112.
144. 144 Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20 (1997), 1183–1197.
145. 145 McCance, D.R., Hanson, R.L., Charles, M.A., Jacobsson, L.T., Pettitt, D.J., Bennett, P.H., et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ 308 (1994), 1323–1328.
146. 146 Engelgau, M.M., Thompson, T.J., Herman, W.H., Boyle, J.P., Aubert, R.E., Kenny, S.J., et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care 20 (1997), 785–791.
147. 147 Levitan, E.B., Song, Y., Ford, E.S., Liu, S., Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 164 (2004), 2147–2155.
148. 148 Wen, C.P., Cheng, T.Y., Tsai, S.P., Hsu, H.L., Wang, S.L., Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. Diabetes Care 28 (2005), 2756–2761.
149. 149 Schinner, S., Futh, R., Kempf, K., Martin, S., Willenberg, H.S., Schott, M., et al. A progressive increase in cardiovascular risk assessed by coronary angiography in non-diabetic patients at sub-diabetic glucose levels. Cardiovasc Diabetol, 10, 2011, 56.
150. 150 Knowler, W.C., Barrett-Connor, E., Fowler, S.E., Hamman, R.F., Lachin, J.M., Walker, E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002), 393–403.
151. 151 Chandalia, M., Garg, A., Lutjohann, D., von Bergmann, K., Grundy, S.M., Brinkley, L.J., Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med 342 (2000), 1392–1398.
152. 152 Hu, F.B., Cho, E., Rexrode, K.M., Albert, C.M., Manson, J.E., Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation 107 (2003), 1852–1857.
153. 153 Mozaffarian, D., Appel, L.J., Van Horn, L., Components of a cardioprotective diet: new insights. Circulation 123 (2011), 2870–2891.
154. 154 Kelley, G.A., Kelley, K.S., Effects of aerobic exercise on lipids and lipoproteins in adults with type 2 diabetes: a meta-analysis of randomized-controlled trials. Public Health 121 (2007), 643–655.
155. 155 Hu, G., Jousilahti, P., Barengo, N.C., Qiao, Q., Lakka, T.A., Tuomilehto, J., Physical activity, cardiovascular risk factors, and mortality among Finnish adults with diabetes. Diabetes Care 28 (2005), 799–805.
156. 156 Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney, P.M., Blackwell, L., Collins, R., Keech, A., Simes, J., Peto, R., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371 (2008), 117–125.
157. 157 Wang, K.L., Liu, C.J., Chao, T.F., Chen, S.J., Wu, C.H., Huang, C.M., et al. Risk of new-onset diabetes mellitus versus reduction in cardiovascular events with statin therapy. Am J Cardiol 113 (2014), 631–636.
158. 158 Liu, P.Y., Lin, L.Y., Lin, H.J., Hsia, C.H., Hung, Y.R., Yeh, H.I., et al. Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study). PLoS One, 8, 2013, e76298.
159. 159 Lai, C.L., Chou, H.W., Chan, K.A., Lai, M.S., Effects of atorvastatin and rosuvastatin on renal function in patients with type 2 diabetes mellitus. Am J Cardiol 115 (2015), 619–624.
160. 160 Chang, S.H., Wu, L.S., Lee, C.H., Kuo, C.T., Liu, J.R., Wen, M.S., et al. Simvastatin-ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: a population-based dynamic cohort study. Int J Cardiol 190 (2015), 20–25.
161. 161 Wang, C.Y., Chang, T.C., Non-HDL cholesterol level is reliable to be an early predictor for vascular inflammation in type 2 diabetes mellitus. J Clin Endocrinol Metab 9 (2004), 4762–4767.
162. 162 Tseng, C.H., Tseng, C.P., Chong, C.K., Cheng, J.C., Tai, T.Y., Independent association between triglycerides and coronary artery disease in Taiwanese type 2 diabetic patients. Int J Cardiol 111 (2006), 80–85.
163. 163 Barzi, F., Patel, A., Woodward, M., Lawes, C.M., Ohkubo, T., Gu, D., et al. A comparison of lipid variables as predictors of cardiovascular disease in the Asia Pacific region. Ann Epidemiol 15 (2005), 405–413.
164. 164 Wen, C.P., Cheng, T.Y., Tsai, M.K., Chang, Y.C., Chan, H.T., Tsai, S.P., et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 371 (2008), 2173–2182.
165. 165 Hung TC, Su CH, Wu YJ, Hung CL, Yeh HI, Wang LY. Cardiovascular risk and lipid management reimbursement between patients with stage 3–5 chronic kidney disease and those with diabetes mellitus. Int J Gerontol. http://dx.doi.org/10.1016/j.ijge.2016.08.001.
166. 166 Chen, L.I., Guh, J.Y., Wu, K.D., Chen, Y.M., Kuo, M.C., Hwang, S.J., et al. Modification of diet in renal disease (MDRD) study and CKD epidemiology collaboration (CKD-EPI) equations for Taiwanese adults. PLoS One, 9, 2014, e99645.
167. 167 Earley, A., Miskulin, D., Lamb, E.J., Levey, A.S., Uhlig, K., Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med 156 (2012), 785–795 W-270, W-1, W-2, W-3, W-4, W-5, W-6, W-7, W-8.
168. 168 Harper, C.R., Jacobson, T.A., Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol 51 (2008), 2375–2384.
169. 169 Lin, T.H., Chuang, S.Y., Chu, C.Y., Lee, W.H., Hsu, P.C., Su, H.M., et al. The impact of chronic kidney disease on lipid management and goal attainment in patients with atherosclerosis diseases in Taiwan. Int J Med Sci 11 (2014), 381–388.
170. 170 Trevisan, R., Dodesini, A.R., Lepore, G., Lipids and renal disease. J Am Soc Nephrol 17 (2006), S145–S147.
171. 171 Vaziri, N.D., Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290 (2006), F262–F272.
172. 172 Fox, C.S., Larson, M.G., Leip, E.P., Culleton, B., Wilson, P.W., Levy, D., Predictors of new-onset kidney disease in a community-based population. JAMA 291 (2004), 844–850.
173. 173 Schaeffner, E.S., Kurth, T., Curhan, G.C., Glynn, R.J., Rexrode, K.M., Baigent, C., et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 14 (2003), 2084–2091.
174. 174 Yamagata, K., Ishida, K., Sairenchi, T., Takahashi, H., Ohba, S., Shiigai, T., et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int 71 (2007), 159–166.
175. 175 Kuo, H.W., Tsai, S.S., Tiao, M.M., Yang, C.Y., Epidemiological features of CKD in Taiwan. Am J Kidney Dis 49 (2007), 46–55.
176. 176 Hattori, M., Nikolic-Paterson, D.J., Miyazaki, K., Isbel, N.M., Lan, H.Y., Atkins, R.C., et al. Mechanisms of glomerular macrophage infiltration in lipid-induced renal injury. Kidney Int Suppl 71 (1999), S47–S50.
177. 177 Hunsicker, L.G., Adler, S., Caggiula, A., England, B.K., Greene, T., Kusek, J.W., et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51 (1997), 1908–1919.
178. 178 Rahman, M., Yang, W., Akkina, S., Alper, A., Anderson, A.H., Appel, L.J., et al. Relation of serum lipids and lipoproteins with progression of CKD: the CRIC study. Clin J Am Soc Nephrol 9 (2014), 1190–1198.
179. 179 Tonelli, M., Muntner, P., Lloyd, A., Manns, B., Klarenbach, S., Pannu, N., et al. Association between LDL-C and risk of myocardial infarction in CKD. J Am Soc Nephrol 24 (2013), 979–986.
180. 180 Chawla, V., Greene, T., Beck, G.J., Kusek, J.W., Collins, A.J., Sarnak, M.J., et al. Hyperlipidemia and long-term outcomes in nondiabetic chronic kidney disease. Clin J Am Soc Nephrol 5 (2010), 1582–1587.
181. 181 Shlipak, M.G., Fried, L.F., Cushman, M., Manolio, T.A., Peterson, D., Stehman-Breen, C., et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 293 (2005), 1737–1745.
182. 182 Sarnak, M.J., Bloom, R., Muntner, P., Rahman, M., Saland, J.M., Wilson, P.W., et al. KDOQI US commentary on the 2013 KDIGO clinical practice guideline for lipid management in CKD. Am J Kidney Dis 65 (2015), 354–366.
183. 183 Stone, N.J., Robinson, J.G., Lichtenstein, A.H., Bairey Merz, C.N., Blum, C.B., Eckel, R.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
184. 184 Tonelli, M., Wanner, C., Lipid management in chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2013 clinical practice guideline. Ann Intern Med 160 (2014), 182–189.
185. 185 Catapano, A.L., Graham, I., De Backer, G., Wiklund, O., Chapman, M.J., Drexel, H., et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 253 (2016), 281–344.
186. 186 National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002), 3143–3421.
187. 187 Kidney Disease Outcomes Quality Initiative (K/DOQI) Group, K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 41:I–IV (2003), S1–S91.
188. 188 Shepherd, J., Kastelein, J.J., Bittner, V., Deedwania, P., Breazna, A., Dobson, S., et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 51 (2008), 1448–1454.
189. 189 Holdaas, H., Fellström, B., Jardine, A.G., Holme, I., Nyberg, G., Fauchald, P., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361 (2003), 2024–2031.
190. 190 KDOQI, KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49 (2007), S12–S154.
191. 191 Colhoun, H.M., Betteridge, D.J., Durrington, P.N., Hitman, G.A., Neil, H.A., Livingstone, S.J., et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 54 (2009), 810–819.
192. 192 Tonelli, M., Isles, C., Curhan, G.C., Tonkin, A., Pfeffer, M.A., Shepherd, J., et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110 (2004), 1557–1563.
193. 193 Navaneethan, S.D., Hegbrant, J., Strippoli, G.F., Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 20 (2011), 146–152.
194. 194 Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J.F., Ruf, G., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005), 238–248.
195. 195 Fellström, B.C., Jardine, A.G., Schmieder, R.E., Holdaas, H., Bannister, K., Beutler, J., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360 (2009), 1395–1407.
196. 196 Hou, W., Lv, J., Perkovic, V., Yang, L., Zhao, N., Jardine, M.J., Cass, A., et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J 34 (2013), 1807–1817.
197. 197 Sniderman, A.D., Tsimikas, S., Fazio, S., The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. J Am Coll Cardiol 63 (2014), 1935–1947.
198. 198 Chiou, K.R., Charng, M.J., Genetic diagnosis of familial hypercholesterolemia in Han Chinese. J Clin Lipidol 10 (2016), 490–496.
199. 199 Singh, S., Bittner, V., Familial hypercholesterolemia—epidemiology, diagnosis, and screening. Curr Atheroscler Rep, 17, 2015, 482.
200. 200 Genest, J., Hegele, R.A., Bergeron, J., Brophy, J., Carpentier, A., Couture, P., et al. Canadian Cardiovascular Society position statement on familial hypercholesterolemia. Can J Cardiol 30 (2014), 1471–1481.
201. 201 Nordestgaard, B.G., Chapman, M.J., Humphries, S.E., Ginsberg, H.N., Masana, L., Descamps, O.S., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 34 (2013), 3478–3490.
202. 202 Raal, F.J., Santos, R.D., Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 223 (2012), 262–268.
203. 203 Cuchel, M., Bruckert, E., Ginsberg, H.N., Raal, F.J., Santos, R.D., Hegele, R.A., et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 35 (2014), 2146–2157.
204. 204 Moorjani, S., Roy, M., Gagne, C., Davignon, J., Brun, D., Toussaint, M., et al. Homozygous familial hypercholesterolemia among French Canadians in Quebec Province. Arteriosclerosis 9 (1989), 211–216.
205. 205 Seftel, H.C., Baker, S.G., Sandler, M.P., Forman, M.B., Joffe, B.I., Mendelsohn, D., et al. A host of hypercholesterolaemic homozygotes in South Africa. Br Med J 281 (1980), 633–636.
206. 206 Lin, J., Wang, L.Y., Liu, S., Wang, X.M., Yong, Q., Yang, Y., et al. A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family. Chin Med J (Engl) 123 (2010), 1133–1138.
207. 207 Alonso, R., Mata, P., Zambon, D., Mata, N., Fuentes-Jimenez, F., Early diagnosis and treatment of familial hypercholesterolemia: improving patient outcomes. Expert Rev Cardiovasc Ther 11 (2013), 327–342.
208. 208 Bruckert, E., Recommendations for the management of patients with homozygous familial hypercholesterolaemia: overview of a new European Atherosclerosis Society consensus statement. Atheroscler Suppl 15 (2014), 26–32.
209. 209 Mombelli, G., Pavanello, C., Novel therapeutic strategies for the homozygous familial hypercholesterolemia. Recent Pat Cardiovasc Drug Discov 8 (2013), 143–150.
210. 210 Patel, N., Hegele, R.A., Mipomersen as a potential adjunctive therapy for hypercholesterolemia. Expert Opin Pharmacother 11 (2010), 2569–2572.
211. 211 Raal, F.J., Santos, R.D., Blom, D.J., Marais, A.D., Charng, M.J., Cromwell, W.C., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375 (2010), 998–1006.
212. 212 McGowan, M.P., Moriarty, P.M., Backes, J.M., The effects of mipomersen, a second-generation antisense oligonucleotide, on atherogenic (apoB-containing) lipoproteins in the treatment of homozygous familial hypercholesterolemia. Clin Lipidol 9 (2014), 487–503.
213. 213 Perry, C.M., Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia. Am J Cardiovasc Drugs 13 (2013), 285–296.
214. 214 Raal, F.J., Lomitapide for homozygous familial hypercholesterolaemia. Lancet 381 (2013), 7–8.
215. 215 Rader, D.J., Kastelein, J.J., Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 129 (2014), 1022–1032.
216. 216 Lyseng-Willliamson, K.A., Perry, C.M., Lomitapide: a guide to its use in adults with homozygous familial hypercholesterolaemia in the EU. Drugs Ther Perspect 29 (2013), 373–378.
217. 217 Cuchel, M., Meagher, E.A., du Toit Theron, H., Blom, D.J., Marais, A.D., Hegele, R.A., et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 381 (2013), 40–46.
218. 218 Blom, D.J., Fayad, Z.A., Kastelein, J.J.P., Larrey, D., Makris, L., Schwamiein, C., et al. LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: rationale and design. J Clin Lipid 10 (2016), 273–282.
219. 219 Blom, D.J., Kastelein, J.J., Larrey, D., Makris, L., Schwamiein, C., Phillips, H., et al. Lomitapide Observational Worldwide Evaluation Registry (LOWER): one-year data [Abstract]. Circulation, 132, 2015, A10818.
220. 220 Raal, F.J., Honarpour, N., Blom, D.J., Hovingh, G.K., Xu, F., Scott, R., et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 385 (2015), 341–350.